

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Wilcox 1



Continu 1									
Section 1. Identifying Inform	ation								
Given Name (First Name) Matthew	2. Surname (Last Nar Wilcox	ne)		3. Date 09-November-2020					
4. Are you the corresponding author?	✓ Yes No								
5. Manuscript Title The Rheological properties of an alginate satiety formulation in a physiologically relevant Human model gut system									
6. Manuscript Identifying Number (if you kn AOE-2020-EBMG-05 (AOE-20-89)	ow it)								
Section 2. The Work Under Co	onsideration for P	ublication							
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to gran								
If yes, please fill out the appropriate info Excess rows can be removed by pressing	rmation below. If you	u have more than	one entit	ty press the "ADD" button to add a row.					
Name of Institution/Company	Grant? Personal Fees?	Non-Financial Support?	Other?	Comments					
Fechnostics Ltd	✓			Funding for the work					
Section 3. Relevant financial a	activities outcide :	the submitted	work						
Place a check in the appropriate boxes in of compensation) with entities as descriclicking the "Add +" box. You should rep	n the table to indicat bed in the instruction	e whether you hans. Use one line fo	ive financi or each en	itity; add as many lines as you need by					
Are there any relevant conflicts of intere		No							
If yes, please fill out the appropriate info	rmation below.								
Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other?	Comments					
Aelius Biotech			✓	Share holder					

Wilcox 2



Section 4. Intellect	ual Property Pate	ents & Copyrights					
Do you have any patents, w If yes, please fill out the app Excess rows can be removed	ropriate information b	elow. If you have mo	•		a row.		
Patent?	Pending? Issue	Licensed? Roya	lties? Licensee?	Comments			
WO2015075467A3				Model Gut Systems			
Section 5. Polation							
Relation	ships not covered	above					
Are there other relationship potentially influencing, wha			o have influenced, or th	nat give the appearance of			
Yes, the following relation				est			
No other relationships/conditions/circumstances that present a potential conflict of interest At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							
Section 6. Disclosu	re Statement						
Based on the above disclosubelow.	res, this form will auto	omatically generate a	a disclosure statement,	which will appear in the bo	ж		
Dr. Wilcox reports grants fro submitted work; In addition				Aelius Biotech, outside the			

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Wilcox 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Chater

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support at

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

1

administrative support, etc.



Section 1. Identifying Info	ormation									
1. Given Name (First Name) Peter	2. Surname (Last Name) Chater	3. Date 11-November-2020								
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Matthew Wilcox								
5. Manuscript Title The Rheological properties of an alg	5. Manuscript Title The Rheological properties of an alginate satiety formulation in a physiologically relevant Human model gut system									
6. Manuscript Identifying Number (if you know it) AOE-2020-EBMG-05 (AOE-20-89)										
Section 2. The Work Unde	r Consideration for Publi	cation								
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No										
Section 3. Relevant finance	ial activities outside the	submitted work.								
of compensation) with entities as de	scribed in the instructions. U I report relationships that we terest?	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication .								
Name of Entity	Grant.	n-Financial Other? Comments								
Aelius Biotech		I am a sharefolder in Aelius Biotech - a company involved in gastrointestinal modelling.								
Section 4. Intellectual Pro	perty Patents & Copyri	ghts								
Do you have any patents, whether p If yes, please fill out the appropriate Excess rows can be removed by pres	information below. If you hav	roadly relevant to the work? Yes No we more than one entity press the "ADD" button to add a row.								

Chater 2



Patent?		Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments		
E	P3074769A2			√					
	Section 5.	Relationshi	ps not cov	ered abo	ove				
	Are there other repotentially influe					eive to have	influenced, or tha	at give the appearance of	
		wing relationsh tionships/cond	-				plain below):	st	
		nuscript accep	otance, journ	als will as	k authors to	o confirm an	d, if necessary, up	date their disclosure stat	ements.
	Section 6.	Disclosure S	Statement						
	Based on the abo	ve disclosures,	, this form wi	ll automa	tically gene	erate a disclo	sure statement, v	vhich will appear in the b	ох
	Dr. Chater report issued.	s other from A	elius Biotech	, outside	the submit	ted work; In	addition, Dr. Cha	iter has a patent EP30747	69A2

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Chater 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Stanforth 1



Section 1.	Identifying Inform	ation					
1. Given Name (Fii Kyle	rst Name)	2. Surnam Stanforth	e (Last Name)			3. Date 13-November-2020	
4. Are you the cor	responding author?	Yes	√ No	Correspond Matthew ¹	ding Author's I Wilcox	Name	
5. Manuscript Title The Rheological		e satiety fo	rmulation in a	a physiologic	ally relevant	Human model gut system	
6. Manuscript Ider AOE-2020-EBMG	ntifying Number (if you kn -05 (AOE-20-89)	ow it)					
	l						
Section 2.	The Work Under Co	onsiderati	on for Publ	ication			
any aspect of the s statistical analysis,	ubmitted work (including	but not limit	ted to grants, d			commercial, private foundati design, manuscript preparati	
If yes, please fill o	out the appropriate info	rmation be	low. If you ha	ve more thar	one entity p	oress the "ADD" button to a	add a row.
Excess rows can l	oe removed by pressing						
Name of Institut	ion/Company	Grant?	_	on-Financial Support?	Other C	Comments	
Technostics		✓			Fur	nding for the work	
Section 3.	Relevant financial	activities (outside the	submitted	work.		
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication .							
Are there any rele	evant conflicts of intere	est? Ye	es 🗸 No				
Section 4.	Intellectual Proper	ty Pater	nts & Copyri	ights			
Do you have any	patents, whether plani	ned, pendin	ng or issued, b	proadly releva	nt to the wo	ork? Yes 🗸 No	

Stanforth 2



Section 5. Polotionships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Mr. Stanforth reports grants from Technostics, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Stanforth 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Woodcock 1



Section 1.	Identifying Inform	nation								
1. Given Name (Fi Andrew	rst Name)	2. Surname (Last Name) Woodcock	3. Date 13-November-2020							
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Name Matthew Wilcox							
•	5. Manuscript Title The Rheological properties of an alginate satiety formulation in a physiologically relevant Human model gut system									
	6. Manuscript Identifying Number (if you know it) AOE-2020-EBMG-05 (AOE-20-89)									
Section 2.	The Work Under C	onsideration for Pub	plication							
any aspect of the s statistical analysis, Are there any rel	Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No									
Section 3.	Relevant financial	activities outside th	e submitted work.							
of compensation	n) with entities as descr	ibed in the instructions.	whether you have financial relationships (regardless of amount Use one line for each entity; add as many lines as you need by were present during the 36 months prior to publication .							
	evant conflicts of intere									
If yes, please fill o	out the appropriate info	ormation below.								
Name of Entity		Grant? Personal Fees?	Ion-Financial Other? Comments							
Technostics			☐ Employer							
Section 4.	Intellectual Prope	rty Patents & Copy	rights							
Do you have any	patents, whether plan	ned, pending or issued,	broadly relevant to the work? Yes Yes							

Woodcock 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Biodonya Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Woodcock reports other from Technostics, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Woodcock 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Dettmar 1



Section 1.	Identifying Inform	nation								
1. Given Name (Fii Peter	Given Name (First Name) Peter			3. Date 13-November-2020						
4. Are you the cor	responding author?	Yes	✓ No	Correspond Matthew \	ding Author's I Wilcox	Name				
•	5. Manuscript Title The Rheological properties of an alginate satiety formulation in a physiologically relevant Human model gut system									
·	6. Manuscript Identifying Number (if you know it) AOE-2020-EBMG-05 (AOE-20-89)									
Section 2.	The Work Under C	onsiderati	on for Publi	cation						
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No										
Section 3.										
Section 5.	Relevant financial	activities (outside the	submitted	work.					
of compensation clicking the "Add	the appropriate boxes i) with entities as descr i +" box. You should re evant conflicts of inter	ribed in the i port relatior	nstructions. U ships that we	se one line fo	or each entity	y; add as many li	nes as you need			
•	out the appropriate inf									
Name of Entity		Grant?		n-Financial Support	Other? C	comments				
Technostics					✓ Em	ployer				
Section 4.	Intellectual Prope	rty Pat <u>e</u> r	nts & Copyri	ghts						
If yes, please fill o	patents, whether plar out the appropriate inf be removed by pressir	ormation be	low. If you hav	-			No outton to add a	row.		

Dettmar 2



Patent?	Pending?	Issued?	Licensed ?	Royalties?	Licensee?	Comments	
EP1931222B1		✓				'Gelling Compositions and Methods'	
Section 5. Relationsl	hips not cove	ered abo	ve				
Are there other relationships of potentially influencing, what y				eive to have	influenced, or t	hat give the appearance of	
Yes, the following relation	ships/condition	ns/circum	istances are	e present (ex	plain below):		
No other relationships/cor	•			•	•	est	
At the time of manuscript according of the control							ents.
		crose rare		ation about	eported relation		
Section 6. Disclosure	Statement						
Based on the above disclosure below.	es, this form wi	ll automat	tically gene	erate a disclo	sure statement,	which will appear in the box	
Dr. Dettmar reports other from EP1931222B1 issued.	n Technostics,	outside t	he submitt	ted work; In	addition, Dr. De	ttmar has a patent	

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Dettmar 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Pearson 1



Section 1. Identifying Inform			
Identifying Inform	mation		
Given Name (First Name) Jeffrey	2. Surname (Last Name) Pearson		3. Date 13-November-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Autho Matthew Wilcox	r's Name
5. Manuscript Title The Rheological properties of an algina	ate satiety formulation in a	a physiologically releva	nt Human model gut system
6. Manuscript Identifying Number (if you k AOE-2020-EBMG-05 (AOE-20-89)	now it)		
Section 2. The Work Under C	Consideration for Publ	ication	
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interpretation of the submitted work (including statistical analysis, etc.)? If yes, please fill out the appropriate interpretation with the submitted work (including statistical analysis). Name of Institution/Company	rest? Yes No formation below. If you ha ng the "X" button. Grant? Personal No	-	cy press the "ADD" button to add a row. Comments
Technostics Ltd	✓		Funding for the work
Place a check in the appropriate boxes of compensation) with entities as desc	ribed in the instructions. ${\sf U}$	hether you have financ Jse one line for each en	tity; add as many lines as you need by
clicking the "Add +" box. You should re Are there any relevant conflicts of inter	•	ere present during the	36 months prior to publication.
If yes, please fill out the appropriate in			
Name of Entity	Grant	on-Financial Other?	Comments
Aelius Biotech			Share holder

Pearson 2



Section 4. Int	ellectual Property -	- Patents & Copy	rights			
If yes, please fill out th	ents, whether planned, he appropriate informa emoved by pressing the	ition below. If you h	•		Yes No he "ADD" button to add	a row.
Patent?	Pending?	Issued? Licensed	Royalties? Lie	icensee?	Comments	
WO2015075467A3		✓		М	lodel Gut Systems	
Section 5.						
Section 5. Re	lationships not cov	ered above				
	onships or activities thang, what you wrote in the			uenced, or that g	give the appearance of	
	relationships/conditionships/conditions/circur					
	cript acceptance, journ may ask authors to dis				ate their disclosure state ips.	ments.
Section 6.						
Dis	sclosure Statement					
Based on the above of below.	lisclosures, this form w	ill automatically ger	nerate a disclosure	e statement, wh	ich will appear in the bo	Х
	grants from Technostics addition, Dr. Pearson ha				elius Biotech, outside the	2

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Pearson 3